|Disclosure:||Dr. Reynolds has modest consultant relationships with Biosense-Webster, Inc. and Medtronic.|
|Pub Date:||Thursday, March 27, 2014|
|Authors:||Matthew Reynolds, MD, MSc|
|Affiliation:||Director, Economics and Quality of Life Research, Harvard Clinical Research Institute, Boston, MA. Associate Professor of Medicine, Tufts University School of Medicine|
CitationAnderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hlatky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw LJ. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines [published online ahead of print March 27, 2014]. Circulation. DOI: 10.1161/CIR.0000000000000042.
For 30 years, the ACC and AHA have been developing consensus guidelines intended to inform medical practice, using methodologies that have been adopted by virtually all other major medical specialty societies. In many ways, cardiovascular medicine has provided leadership in generating, synthesizing, evaluating, and interpreting clinical evidence on which to base clinical decision-making. To a large extent, these guideline documents have come to define evidence-based standards of care in our specialty.
Until now, ACC/AHA guideline committees have not explicitly considered issues related to cost, cost-effectiveness, or “value” when developing their documents. With the publication of a new ACA/AHA committee statement,1 however, it appears that the long-standing practice of not directly addressing cost issues in guideline documents will soon change.
The cost methodology statement was written by a committee of cardiologists and experts in health economics research, under the auspices of ACC/AHA Task Forces on Performance Measures and Practice Guidelines. In addition to providing general background on the rationale and challenges involved in considering health economics in guideline statements as well as background on basic health economic research methods, the document makes several concrete recommendations on how to begin implementing assessments of cost or value into the guidelines process.
Among the important recommendations are the following.
The writing committee has tackled a thorny issue in health care, and done a thorough and commendable job of discussing the major issues. There is currently no question that US healthcare spending has for many years been on an unsustainable trajectory. All stakeholders, including physicians, need to be involved in improving the value of medical care.
That said, the incorporation of value assessments into practice guidelines will not be simple or without controversy. First, many common clinical strategies lack good quality evidence regarding value. Even when good quality evidence is available, however, it is not clear how, or even if, it should be used in clinical care. Practice guidelines have always aspired to assist clinical decision-making at the individual patient level. Health economics research, on the other hand, generally aims to inform policy making at a much broader (health system or societal) level. While the writing committee attempted to describe some scenarios of how value assessments might be used, they emphasized that “the goal of incorporating considerations of value into guideline recommendations should be to provide information rather than to be prescriptive.”
This overriding position of not being “prescriptive” is practical, but raises questions about how impactful this entire exercise may be, at least in the short term. One point made by the authors that bears repeating here, is that consensus guidelines to a certain extent have always implicitly addressed the concept of value by identifying and expressly discouraging clinical practices known to be ineffective, i.e. Class III recommendations. Ineffective care always has poor value. The authors also rightly point out that endorsing certain clinically effective practices as high value could help “guard against the unintended consequences of capitation-based reimbursement.”
If the clinical response to high value interventions is straightforward, what then should happen for interventions of intermediate or low value? It is here where physicians’ dual obligations to advocate for their patients while simultaneously acting as responsible stewards of societal resources may conflict. The committee suggested that value assessments could potentially be used as a sort of “tie-breaker” in cases where the clinical evidence is equivocal. The committee stops short, however, of declaring that low value interventions should never be adopted, acknowledging that in “exceptional cases, a resource-intensive therapy may provide the only effective/life-saving treatment available” and thus may “be considered by society as appropriate.” It would seem then, that clinical considerations could still trump value considerations in some unusual cases where clinical evidence and value evidence point in different directions.
It will be interesting to see how other players in the system, in particular government and private insurers, respond to the incorporation of value evidence into ACC/AHA guideline statements. Unintended consequences are always possible, and should be guarded against. Whatever those reactions may be, it is the committee’s stance that value issues in cardiovascular medicine are sufficiently important that they deserve detailed scrutiny in the guideline development process, and frank discussion in guideline documents – and beyond.
- Anderson JL, Heidenreich PA, Creager MA, Fonarow GC, Gibbons RJ, Hlaperin JL, Hlatky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw LJ. ACC/AHA Cost Methodology: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; (in press)
- World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE): Cost Effectiveness Thresholds. Available at: http://www.who.int/choice/costs/CER_thresholds/en/index.html.
-- The opinions expressed in this commentary are not necessarily those of the editors or of the American Heart Association --